DOVOBET GEL 0.5 MG
BETAMETHASONE (BETAMETHASONE DIPROPIONATE) : 0.5 MG CALCIPOTRIOL (CALCIPOTRIOL MONOHYDRATE) : 50 MCG · DIN 02319012 · LEO PHARMA INC
Health Canada status: MARKETED
What is DOVOBET GEL?
DOVOBET GEL 0.5 MG contains BETAMETHASONE (BETAMETHASONE DIPROPIONATE) : 0.5 MG CALCIPOTRIOL (CALCIPOTRIOL MONOHYDRATE) : 50 MCG. It is listed in the Health Canada Drug Product Database under DIN 02319012, held by LEO PHARMA INC, supplied as GEL for TOPICAL administration. Health Canada currently lists it as marketed, status dated 12-Oct-2012. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is DOVOBET GEL used for?
Topical treatment of moderate to severe scalp psoriasis vulgaris (up to 4 weeks) and mild to moderate plaque psoriasis vulgaris on the body (up to 8 weeks) in patients 18 years and older.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02319012 |
|---|---|
| Brand name | DOVOBET GEL |
| Generic / active ingredient | BETAMETHASONE (BETAMETHASONE DIPROPIONATE) : 0.5 MG CALCIPOTRIOL (CALCIPOTRIOL MONOHYDRATE) : 50 MCG |
| Manufacturer | LEO PHARMA INC |
| Strength | 0.5 MG |
| Dosage form | GEL |
| Route of administration | TOPICAL |
| Schedule | Prescription |
| ATC code | D05AX52 CALCIPOTRIOL, COMBINATIONS |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 12-Oct-2012 |
How is it administered?
Apply once daily to affected areas for up to 4 weeks (scalp) or 8 weeks (body). Max 15 g/day and 100 g/week of calcipotriol products. Total treated area should not exceed 30% BSA.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not explicitly detailed in the provided text summary (refer to STORAGE AND STABILITY section 18, page 18).
How is it supplied?
Available in a bottle format.
Contraindications
Hypersensitivity; ophthalmic use; calcium metabolism disorders; viral, fungal, bacterial, or parasitic skin infections; skin atrophy; various psoriasis types (guttate, erythrodermic, etc.).
Warnings and precautions
Risk of hypercalcemia, hypercalciuria, and HPA axis suppression. Do not use on face, flexures, or genitals. Avoid excessive sunlight exposure. Potential for skin carcinogenicity with UVR.
What can be used instead?
Other Canadian products sharing ATC code D05AX52 CALCIPOTRIOL, COMBINATIONS. 4 of 4 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| DOVOBET OINTMENT | 50 MCG | OINTMENT | LEO PHARMA INC | MARKETED | DIN 02244126 |
| ENSTILAR | 0.5 MG | AEROSOL, FOAM | LEO PHARMA INC | MARKETED | DIN 02457393 |
| TARO-CALCIPOTRIOL / BETAMETHASONE GEL | 50 MCG | GEL | TARO PHARMACEUTICALS INC | MARKETED | DIN 02525178 |
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.